Circulation publishes phase I study of ENBREL in patients with chronic heart failure

SEATTLE - A Phase I study published today in CIRCULATION: Journal of the American Heart Association, demonstrates ENBREL® (etanercept, a soluble TNF p75 receptor) was well tolerated in patients with advanced heart failure. The study also suggests that ENBREL may lead to improvement in the functional status of patients with chronic heart failure. This is the first published paper of an ENBREL study in chronic heart failure.

The study was conducted by Dr. Douglas Mann of the Veterans Administration Medical Center and Baylor College of Medicine in Houston Texas and Immunex Corporation, Seattle WA. The randomized, double-blind dose escalation study consisted of 18 patients with New York Heart Association class III heart failure and elevated TNF levels. Patients were randomized to receive a single intravenous infusion of one of three doses of ENBREL or placebo. Patients receiving ENBREL had increased quality of life scores, with a 6-minute walk distance and ejection fraction from baseline while those on placebo had no significant increases in these measurements from baseline. ENBREL was well tolerated without any significant adverse effects.


Immunex Corporation (NASDAQ:IMNX) and Wyeth-Ayerst Laboratories began a Phase II/III clinical trial (called the RENAISSANCE Trial - Randomized ENBREL North American Strategy to study Antagonism of Cytokines) with ENBREL® (etanercept) in chronic heart failure patients, one of the first large-scale studies undertaken to evaluate cytokine inhibition, a new approach to studying chronic heart failure.

The Role of TNF in Chronic Heart Failure

Research has shown that tumor necrosis factor TNF is present in increased amounts in damaged heart tissue. TNF exerts its effects by interacting with specific TNF receptors that are on the surface of cells. When TNF binds with TNF receptors, it sets off a chain of events within the cell that may lead to further damage to the heart.


Contact: Pam Rabe
Immunex Corporation

Page: 1 2 3

Related medicine news :

1. Report in Circulation urges a closer look at cardiotoxicity of cancer drug trastuzumab (Herceptin)
2. Association publishes blueprint to strengthen stroke care from prevention through recovery
3. EUROCARE3 publishes new childhood cancer survival figures
4. ACP publishes Medical Meanings, second edition
5. Nuclear Cardiac Imaging: Society of Nuclear Medicine publishes new book
6. ACP-ASIM books program publishes Osteoporosis
7. Institute publishes "Principles of Drug Addiction Treatment"
8. US FDA grants full approval to DOXIL(R) following submission of phase III data
9. Less risks for patients participating in early phase cancer drug trials
10. Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection
11. Exemestane beats tamoxifen in first phase III head to head trial in advanced breast cancer

Post Your Comments:

(Date:12/6/2019)... ... ... Lasair Aesthetic Health Sponsors Toys for Tots to Give Free Toys to Children in Need ... Toys During the Holidays , Lasair Aesthetic Health is spreading holiday cheer again this year ... a toy or toys worth more than 25-dollars, will get FIVE units of Botox (a ...
(Date:12/6/2019)... ... , ... TIME For Kids (TFK) revealed the first-ever list of ... fun destinations that are tailored to the interests of kids. The list identifies The ... the list, TIME for Kids gathered nominations from its network of TFK Kid ...
(Date:12/5/2019)... (PRWEB) , ... December 05, 2019 , ... Abide, the ... over 25 million times this year using Bible-based bedtime stories. Listeners have recovered from ... , According to the Center for Disease Control, one third of Americans suffer from ...
(Date:12/5/2019)... GILBERT, Ariz. (PRWEB) , ... December 05, 2019 ... ... International , with milestones ranging from launching exceptional products that help people embrace, ... around the world. , “We’ve never been more committed to our mission of ...
(Date:12/4/2019)... ... December 04, 2019 , ... Now a ... protection from disruptions to cells and tissue and inflammation that leads to Jet ... is available in a dietary supplement product called Prepair™ . , Today, ...
Breaking Medicine News(10 mins):
(Date:12/5/2019)... (PRWEB) , ... December 05, 2019 , ... ... education planning, has announced the Top 27 Respiratory Therapy Degree Programs for 2020. ... and universities in the nation. Each program is evaluated based on curriculum quality, ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
(Date:12/2/2019)... ... December 02, 2019 , ... ... A Mission for Michael, an intensive mental health facility, announced it has named ... client relations, business development and national advocacy efforts. , "We are proud to ...
Breaking Medicine Technology:
Cached News: